Sanofi S.A., FR0000120578

Sanofi stock: JPMorgan keeps EUR 85.00 target for Sanofi stock

Published on 10/23/2026 at 15:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi reports third-quarter results on October 30, 2026. Sanofi stock costs EUR 74.52 on October 23, 2026, down 0.57 percent versus the Euronext Paris close.

Analyst target and trial data

JPMorgan retained its Neutral rating and EUR 85.00 target on October 21, 2026.
Duvakitug produced 58.00 percent clinical remission at 900 mg after 44 weeks.
Sanofi stock costs EUR 74.52 at Lang & Schwarz on October 23, 2026 at 3:35 p.m. CEST, down 0.57 percent versus the October 22 close.
Sanofi will publish third-quarter 2026 results on October 30, 2026.

Isometric 3D render of a translucent violet-blue cube containing a glowing molecular structure, a vaccine vial, a tablet blister pack, and a laboratory microscope — Sanofi FR0000120578 isometric 3D violet cube enclosing molecular structure, vaccine vial, blister pack, and microscope, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) remains under an EUR 85.00 target after JPMorgan retained its Neutral rating on October 21, 2026, according to MarketScreener. The target is 14.06 percent above the EUR 74.52 Lang & Schwarz price. Sanofi was trading at EUR 74.52 at Lang & Schwarz on October 23, 2026 at 3:35 p.m. CEST, down 0.57 percent versus the Euronext Paris close of October 22, 2026 at EUR 74.95.

Duvakitug reaches 58.00 percent remission

The latest clinical update gives Sanofi a measurable pipeline milestone ahead of its third-quarter report. In a release dated October 20, 2026, Sanofi said the phase 2b RELIEVE UCCD extension study followed 130 patients through 44 weeks. In ulcerative colitis, clinical remission reached 47.00 percent at 450 mg and 58.00 percent at 900 mg. Clinical response reached 82.00 percent and 87.00 percent, respectively.

The higher dose also produced 63.00 percent endoscopic improvement, versus 59.00 percent at 450 mg. The results are descriptive, and duvakitug remains under clinical investigation rather than approved for commercial use.

Stock stays below its yearly range

Sanofi's Euronext Paris price was EUR 74.15 at 11:10 a.m. CEST on October 23, 2026, down 1.07 percent on the day, according to a MarketScreener market page. The same page listed a 10.34 percent decline since January 1, 2026 and a last close of EUR 74.95. The Lang & Schwarz quote was therefore EUR 0.43 below that dated Euronext close.

Results date sets the next test

Sanofi's investor calendar lists third-quarter 2026 results for October 30, 2026, with a webcast scheduled from 1:30 p.m. to 2:30 p.m. CET. The calendar also lists the Jefferies Global Healthcare Conference in London for November 17, 2026. Both dates come from Sanofi.

The upcoming report will put the EUR 85.00 analyst target alongside operating results, while the duvakitug figures provide a separate pipeline reference. The current euro quote remains below the target by EUR 10.48.

Price and upcoming dates

Sanofi was trading at EUR 74.52 at Lang & Schwarz on October 23, 2026 at 3:35 p.m. CEST, down 0.57 percent versus the Euronext Paris close of October 22, 2026 at EUR 74.95. The next scheduled corporate date is October 30, 2026 for third-quarter results. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.